Furthermore MITOL is required for degradation of mitochondrial fusion protein Mfn1 in LNCaP prostate cancer cells treated with CGP37157 (CGP), an inhibitor of mitochondrial calcium efflux, and resulted in mitochondrial fission. Here, MFN1 is linked to prostate cancer.